Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Hedgehog signaling pathway is a critical regulator of embryonic development and adult tissue homeostasis. It consists of several key molecular components including the secreted ligand Sonic hedgehog (SHH), its primary receptor Patched 1 (PTCH1), the signal transducer Smoothened (SMO), and downstream transcription factors such as the GLI family. Activation begins when SHH binds PTCH1 on target cells, relieving inhibition on SMO and triggering intracellular cascades that ultimately regulate gene expression via GLI transcription factors. Aberrant activation or mutation within this pathway is implicated in various cancers—including basal cell carcinoma—and developmental disorders. Several drugs targeting SMO are approved for cancer therapy; however, safety concerns exist due to the essential role of this pathway in normal tissue maintenance and embryogenesis[1][2].
Inhibition of Smoothened to block downstream Hedgehog signal transduction
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hedgehog signaling pathway component (Hh pathway component).